Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of propranolol hydrochloride and pembrolizumab in
treating patients with urothelial cancer that has come back (recurrent) or has spread to
other places in the body (metastatic). Propranolol hydrochloride is used for the treatment of
chronic angina, cardiac arrhythmias, essential tremor, hypertension, and as prophylaxis for
migraine headaches, and may have anticancer properties. Immunotherapy with monoclonal
antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Giving propranolol
hydrochloride and pembrolizumab may enhance the anticancer activity of pembrolizumab.